Innate PharmaIPH
▼ NegativeCapitalrelevance
Innate Pharma reported a first-half GAAP loss of €0.21 per share and a sharp drop in cash to €21.4 million from €44.8 million.
Impact on stocks 1
Biotech & Genomic Medicine
Innate PharmaInnate Pharma reported a first-half GAAP loss of €0.21 per share, with revenue of €5.7 million, up 16.3% year over year. Cash, cash equivalents, short-term investments and non-current financial assets totaled €21.4 million as of June 30, 2026, down from €44.8 million as of December 31, 2025. The results were released in the company's first-half 2026 business update and financial results.
Innate PharmaInnate Pharma reported a first-half GAAP loss of €0.21 per share and a sharp drop in cash to €21.4 million from €44.8 million.